Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non Operating Income (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non Operating Income for 5 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 99.12% to $57000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 84.92% decrease, with the full-year FY2025 number at $1.3 million, down 85.8% from a year prior.
  • Other Non Operating Income was $57000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $275000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $100.0 million in Q1 2021 to a low of -$644000.0 in Q1 2025.
  • A 5-year average of $6.4 million and a median of $57000.0 in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 8025.0% in 2023, then skyrocketed 2040.74% in 2024.
  • Rhythm Pharmaceuticals' Other Non Operating Income stood at $100.0 million in 2021, then crashed by 100.42% to -$420000.0 in 2022, then soared by 233.1% to $559000.0 in 2023, then surged by 1056.71% to $6.5 million in 2024, then plummeted by 99.12% to $57000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Other Non Operating Income are $57000.0 (Q4 2025), $275000.0 (Q3 2025), and $1.6 million (Q2 2025).